Clindamycin Topical

Contraindicated

Clindamycin Topical Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Clindamycin Topical Levoketoconazole Recorlev Increased CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related adverse reaction Details Clindamycin Topical Mifepristone Korlym Increased CYP3A4 substrate with NTI exposure Details

Major

Clindamycin Topical Apalutamide Erleada Reduced CYP3A4 substrate exposure Details Clindamycin Topical Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Clindamycin Topical Avacopan Tavneos Increased exposure to CYP3A4 substrate Details Clindamycin Topical Belzutifan Welireg Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Clindamycin Topical Berotralstat Orladeyo Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Clindamycin Topical Carbamazepine Carbatrol Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Clindamycin Topical Ceritinib Zykadia Increased exposure of CYP3A substrate Details Clindamycin Topical Cholera Vaccine, Live Reduced immune response to the cholera vaccine Details Clindamycin Topical Clarithromycin Biaxin Increased exposure of CYP3A4 substrate and risk for toxicity Details Clindamycin Topical Conivaptan Vaprisol Increased CYP3A substrate exposure Details Clindamycin Topical Crizotinib Xalkori Increased exposure of the CYP3A substrate Details Clindamycin Topical Daridorexant Increased CYP3A4 substrate with NTI exposure Details Clindamycin Topical Elinzanetant Lynkuet Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Clindamycin Topical Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Clindamycin Topical Enzalutamide Xtandi Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Clindamycin Topical Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Clindamycin Topical Exenatide Bydureon Reduced oral antibiotics absorption and reduced efficacy of oral antibiotics Details Clindamycin Topical Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Clindamycin Topical Fluconazole Diflucan Increased sensitive CYP3A4 substrates exposure Details Clindamycin Topical Gepotidacin Blujepa Increased CYP3A4 substrate with NTI exposure Details Clindamycin Topical Imatinib Gleevec Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Clindamycin Topical Itraconazole Sporanox Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Clindamycin Topical Lanreotide Altered exposure to CYP3A4 substrate Details Clindamycin Topical Lazertinib Lazcluze Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Clindamycin Topical Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Clindamycin Topical Letermovir Prevymis Increased CYP3A substrate exposure Details Clindamycin Topical Lonafarnib Zokinvy Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A substrate with NTI-related serious or life-threatening... Details Clindamycin Topical Lorlatinib Lorbrena Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Clindamycin Topical Mavorixafor Xolremdi Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Clindamycin Topical Methotrexate Jylamvo Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Clindamycin Topical Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Clindamycin Topical Mitotane Lysodren Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Clindamycin Topical Mobocertinib Exkivity Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Clindamycin Topical Nirogacestat Ogsiveo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Clindamycin Topical Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Clindamycin Topical Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Clindamycin Topical Pacritinib Vonjo® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details